Lizenzdeal mit Celgene
www.fiercebiotech.com/biotech/...gs-rights-to-macrophage-drug
www.benzinga.com/general/biotech/19/07/...g-deal-with-celgene
Lizenzdeal mit Celgene
www.fiercebiotech.com/biotech/...gs-rights-to-macrophage-drug
www.benzinga.com/general/biotech/19/07/...g-deal-with-celgene
Ende September 2019 war JNCE sogar unter 3$ zu bekommen, mittlerweile fast wieder bei 9$.
Zahlen für Q1/20
"Based on its current operating and development plans, Jounce continues to expect gross cash burn on operating expenses and capital expenditures for the full year 2020 to be approximately $80.0 million to $95.0 million.
Given the strength of its balance sheet, Jounce expects its existing cash, cash equivalents and investments to be sufficient to enable the funding of its operating expenses and capital expenditure requirements through the end of 2021."
ir.jouncetx.com/news-releases/...arter-2020-financial-results
Lizenzvereinbarung mit Gilead für JTX-1811
"Jounce will also be eligible to receive royalties ranging from high single digit to mid-teens based upon worldwide sales, subject to certain adjustments."
ir.jouncetx.com/news-releases/...rapeutics-announce-exclusive
Die EMERGE-Phase2 Studie von vopratelimab in Kombination mit ipilimumab wird nicht fortgeführt
"We are disappointed that an early look at the EMERGE data indicates that we will not meet our pre-specified interim criteria for continued enrollment,” said Beth Trehu, M.D., Chief Medical Officer at Jounce Therapeutics.
ir.jouncetx.com/news-releases/...-update-vopratelimab-program
jouncetx.com/our-pipeline/
Insider-Trades
www.gurufocus.com/stock/JNCE/insider?search=jounce
56 Mio. $ Offering
ir.jouncetx.com/news-releases/...-pricing-5625-million-public
Zahlen für Q1/21
"Given the strength of its balance sheet, Jounce expects its existing cash, cash equivalents and investments to be sufficient to enable the funding of its operating expenses and capital expenditure requirements through the second quarter of 2023."
ir.jouncetx.com/news-releases/...arter-2021-financial-results
Die letzten Insider-Trades waren allesamt Verkäufe
www.gurufocus.com/stock/JNCE/insider?search=jounce
Zahlen für Q2/21
"Based on its current operating and development plans, Jounce continues to expect gross cash burn on operating expenses and capital expenditures for the full year 2021 to be approximately $95.0 million to $110.0 million.
Given the strength of its balance sheet, Jounce expects its existing cash, cash equivalents and investments to be sufficient to enable the funding of its operating expenses and capital expenditure requirements through the third quarter of 2023."
ir.jouncetx.com/news-releases/...econd-quarter-2021-financial
Zahlen für Q3/21
ir.jouncetx.com/news-releases/...arter-2021-financial-results
Schöner Lauf, seit August +90%
Zahlen für Q4/21
ir.jouncetx.com/news-releases/...h-quarter-and-full-year-2021
Zahlen für Q1/22
ir.jouncetx.com/news-releases/...arter-2022-financial-results
Financial Guidance
"Based on its current operating and development plans, Jounce reiterates its financial guidance for 2022. Gross cash burn on operating expenses and capital expenditures for the full year 2022 is expected to be approximately $115.0 million to $130.0 million. Given the strength of its balance sheet, Jounce expects its existing cash, cash equivalents and investments to be sufficient to enable the funding of its operating expenses and capital expenditure requirements through the third quarter of 2023."
Phase2 Lungenkrebs-Studie verfehlt den primären Endpunkt
ir.jouncetx.com/news-releases/...ts-phase-2-randomized-select
seekingalpha.com/news/...cer-therapy-fails-in-mid-stage-trial
Zahlen für Q2/22
- INNATE trial of JTX-8064 +/- pimivalimab on track to present preliminary data on at least 80 Phase 2 patients across multiple cohorts by year end
ir.jouncetx.com/news-releases/...econd-quarter-2022-financial
Zahlen für Q3/22
"Jounce geht nun davon aus, in der ersten Hälfte des Jahres 2023 anstelle von ESMO-IO im Dezember 2022 zusätzliche Ergebnisse aus dem Phase-2-Teil der Studie veröffentlichen zu können. In den vorläufigen Daten von über 80 Patienten in allen Kombinationskohorten, glaubt Jounce es wurden Anzeichen einer klinischen Aktivität von JTX-8064 festgestellt, jedoch keine breite Aktivität, die zu einem schnellen Proof-of-Concept (POC) führte. Die Wirksamkeitsdaten brauchen Zeit, um zu reifen, und die Bewertung, ob POC erreicht wird, basierend auf bestätigtem Ansprechen in jeder vollständig erweiterten Kohorte, wird die Präsentation eines vollständigen und interpretierbaren Datensatzes ermöglichen. Sowohl die JTX-8064-Monotherapie als auch die Pimi-Kombination zeigen bis heute weiterhin ein akzeptables Sicherheitsprofil."
ir.jouncetx.com/news-releases/...arter-2022-financial-results
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
33 | JNCE 3,92$ | Vassago | Vassago | 27.03.23 15:19 |